SILENCE THERAPEUTICS PLC (SLN)
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business